Radiopharm Theranostics (ASX:RAD) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Days Payable?

Radiopharm Theranostics's average Accounts Payable for the six months ended in Dec. 2023 was A$5.99 Mil. Radiopharm Theranostics's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Radiopharm Theranostics's Days Payable or its related term are showing as below:

ASX:RAD's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Radiopharm Theranostics's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Radiopharm Theranostics Days Payable Historical Data

The historical data trend for Radiopharm Theranostics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Days Payable Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Days Payable

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	-	-	-	-	-

Competitive Comparison of Radiopharm Theranostics's Days Payable

For the Biotechnology subindustry, Radiopharm Theranostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Days Payable distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Days Payable falls into.

Radiopharm Theranostics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Radiopharm Theranostics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (1.19	+	2.957)	/	2 )	/	0	*	365
=	2.0735					/	0	*	365
=	N/A

Radiopharm Theranostics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2.957	+	9.019)	/	2 )	/	0	*	365 / 2
=	5.988					/	0	*	365 / 2
=	N/A

Radiopharm Theranostics Days Payable Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (ASX:RAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

RDPTF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines